Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gilead Sciences Plans Western China Ops Center in Chengdu

publication date: Jul 11, 2019

Gilead Sciences signed a strategic cooperation agreement with Chengdu Hi-tech Zone to develop a Western China Operation Center at the Chengdu park. Gilead is known for developing drugs for difficult-to-treat infections, especially HIV/AIDS and hepatitis C. Its first China approval came in 2017 for the hepatitis C treatment Solvadi. In China, Gilead opened a Shanghai commercial office in 2016. Currently, Gilead is conducting clinical trials of sofosbuvir/velpatasvir, the company's single-tablet treatment for HCV, at sites across China. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China